GLP1R and cardiovascular disorder: A 2023 meta-analysis of randomized clinical trials did not report a significant reduction in dementia, and included 21 randomized clinical trials, including DPP-4 inhibitors, GLP1-RAs, and SGLT2is.8 This meta-analysis differed in that the analysis was confined to glucose-lowering therapy with proven effectiveness in reducing the risk of cardiovascular disease, and included additional trials for GLP1-RA and SGLT2i classes.